MRVI Q1 2025 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M-27.0% YoY

Gross Profit

$8M16.5% margin

Operating Income

-$49M-104.9% margin

Net Income

-$30M-63.9% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-16.9%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$15M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$960M

Total Liabilities

$429M

Stockholders' Equity

$301M

Cash & Equivalents

$285M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$64M	-27.0%
Gross Profit	$8M	$26M	-70.1%
Operating Income	-$49M	-$19M	-160.7%
Net Income	-$30M	-$12M	-147.9%

Revenue Segments

Nucleic Acid Production Segment

$29M61%

Biologics Safety Testing Segment

$18M39%

Geographic Segments

North America

$29M62%

Asia Pacific

$11M23%

EMEA

$7M15%

Latin And Central America

$146,0000%